Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Thomas Hanke

Head of Academic Partnerships at Evotec

Thomas Hanke LAB282 Expert in Residence

Evotec is a drug discovery alliance and development partnership company. Since November 2016, Dr Hanke has been responsible for strategic academic partnerships at Evotec. He has also been Executive Vice President of Immunology and Inflammation since November 2013, heading a portfolio of drug discovery projects in the areas of inflammation and immuno-oncology. During this time, Dr Hanke’s focus has been on building high-value, performance based drug discovery alliances with academia and pharma.

Dr. Hanke is in Oxford as LAB282's expert in residence and is working closely with academics and Oxford University Innovation to source and manage funded projects. Read more about LAB282 and Dr Hanke's involvement. 

If you would like to discuss projects please contact Richard Reschen (richard.reschen@innovation.ox.ac.uk)

Dr Andy Pearce

Director, Discovery Partnerships with Academia at GSK

AndyPearce.jpg.pngIn his role Andy leads drug discovery projects from target validation through hit-finding and to the delivery of high quality clinical candidates, across broad disease areas, in collaboration with world-leading academic partners. Prior to joining GSK Andy worked in the Respiratory Therapy Area at Novartis, leading multidisciplinary teams and drug discovery projects delivering multiple novel targets into the portfolio and clinical candidates.

Andy has experience of programs of all major target classes, of localised and oral drug delivery and both small molecule and biopharmaceutical modalities. With over 18 years of experience in target and drug discovery in academia and Pharma companies spanning target identification to early clinical development Andy is well placed to provide advice and guidance on translational research, target validation, assay development, lead optimisation and early preclinical and clinical development.

A biochemist and cell biologist by training, Andy received his undergraduate degree and DPhil from the University of Oxford and undertook postdoctoral studies at the University of Birmingham, identifying and studying novel membrane receptors and their signal transduction pathways. Andy is a Fellow of the Royal Society of Biology, occasionally lectures at Oxford and Cambridge Universities and participates in career panels and workshops for scientists.

Andy can advise on:

  • Drug discovery spanning target identification and validation through to early clinical development.
  • Routes to progress drug discovery and translational projects.
  • Career development for early career researchers.

Andy will sit in the Target Discovery Institute (TDI), Nuffield Department of Medicine, NDM Research Building on various dates during 2018/19. If you would like to arrange a meeting with Andy please contact charlotte.bell@medsci.ox.ac.uk